Joo Mee Kim

Joo Mee Kim is a patent litigation attorney at Rothwell Figg Ernst & Manbeck, with a practice focused on intellectual property advocacy and counsel for a diverse range of clients. Her technical background as a licensed pharmacist in Korea provides a strong foundation for her work with pharmaceutical and life sciences clients, including Hatch-Waxman litigations. Her broader experience encompasses chemicals, cosmetics, and electronics, including handsets, display devices, home appliances, and materials for the IT and semiconductor industries.

Ms. Kim primarily represents defendants and challengers in patent disputes. Her tracked appearances show her exclusively on the defendant side in U.S. patent litigation. This aligns with her firm profile, which highlights her work defending companies like Mylan Pharmaceuticals, LG Electronics, Rexall, Inc., Nature's Bounty, Celltrion, LG Chem, and AmorePacific in patent litigations, arbitrations, and post-grant review cases.

A significant portion of Ms. Kim's practice involves Patent Trial and Appeal Board (PTAB) proceedings, including Inter Partes Review (IPR) and Post-Grant Review (PGR). She notably served as counsel for Celltrion, Inc. in IPR proceedings against Regeneron Pharmaceuticals, Inc., where Celltrion successfully challenged Regeneron's patents, leading to Regeneron disclaiming claims and dismissing appeals. Additionally, Ms. Kim was part of the Rothwell Figg team that secured a rare Motion to Amend grant from the PTAB for LG Chem, Ltd. in an IPR concerning anti-fingerprint coatings.

Prior to her U.S. practice, Ms. Kim was a licensed pharmacist and a patent attorney in Korea, representing major pharmaceutical and chemical clients in patent infringement cases. She moved to the United States in 1998, where she passed bar exams and gained experience in patent prosecution and opinion work, particularly in genetic engineering, molecular biology, and biotechnology, before joining Rothwell Figg. She is admitted to practice in the District of Columbia and before the U.S. Patent and Trademark Office.